Maxime Dougados

TL;DR: In this article , the long-term safety, tolerability, and efficacy of bimekizumab in patients with active ankylosing spondylitis (AS) were assessed.

TL;DR: The outcome of RDKOA seems less severe than expected after global medical treatment, and functional impairment, assessed by the maximal walking time, and radiological severity in extension were baseline predisposing factors of subsequent requirement to knee surgery.

TL;DR: In the majority of patients, innovator infliximab can be switched to biosimilars of originator biologic therapeutics without changes in efficacy and safety during 34 weeks follow-up, however, 26% of patients discontinued biosimilar inflIXimab, mainly those with AxSPA due to a subjective increase in BASDAI or ASDAS scores, possibly explained by suggestion or attribution effects rather than pharmacological differences.

TL;DR: Ten recommendations for the use of methotrexate were recently developed, based on published data and expert opinion in the 3E initiative, and it is necessary after they have been published to facilitate their dissemination.

TL;DR: Responses with BKz were rapid, including in PBO pts who switched to BKZ at Wk 16, and increased to Wk 24, and all ranked secondary endpoints were met (Table 1).